secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-05-22T20:15:37+00:00
Accession:  0001104659-26-065728
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity of $1.25M vs $2.5M minimum
--------------------------------------------------------------------------------

- Stockholders' equity as of March 31, 2026 was $1,251,427, below Nasdaq's $2,500,000 minimum requirement.
- Company has 45 days (until July 3, 2026) to submit a compliance plan to Nasdaq.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- Failure to regain compliance could lead to delisting of common stock (RNAZ) from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/0001104659-26-065728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/tm2615385d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-065728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer